(and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings
BPC-157 may be less appropriate for those with a history of cancer or active malignancy, individuals uncomfortable with the investigational nature of peptide therapy, people unable to commit to consistent daily administration for 4-8 weeks, those seeking instant results rather than gradual healing, and anyone who cannot source pharmaceutical-grade products from reputable suppliers
This heterogeneity may be attributed to differences in baseline HbA1c levels, obesity prevalence, trial duration, comparator treatments, dosing strategies, and outcome definitions
However, further research is required to establish how to use these drugs to produce optimal outcomes for kidney pathology